Bone marrow/stem cell transplant survivors need a comprehensive plan for long-term follow-up care. This presentation discusses the challenges survivors face in accessing this care and strategies to overcome these challenges.

This presentation outlines the importance of long-term follow-up care after a bone marrow/stem cell transplant using donor cells (allogeneic transplant) focused on supportive care for side effects post-transplant, identifying new health issues early, and providing resources and guidance to ensure the patient is experiencing their optimal quality of life after treatment.

This presentation discusses what a clinical trial is, why they are necessary, the phases of a clinical research trials, how they are reviewed to ensure patient safety, the process involved in participating in a clinical trial, and where one can go to receive further information about clinical trials. 

Many treatment options are being studied and utilized for patients whose cancer has relapsed (come back) after a bone marrow/stem cell transplant or CAR T-cell therapy. Many clinical trials are showing increased survival outcomes, and some of these new therapies have replaced previous treatment standards.

Even when cancer treatment is initially successful, many patients experience a fear of recurrence of their illness. This presentation discusses the causes of such fears, and coping strategies that survivors can use to manage them.

This presentation provides an overview of various long-term effects that may occur after an autologous stem cell transplant, and provides strategies and advice for how these effects might be managed.

Graft-versus-host disease (GVHD) is a common side effect of an allogeneic transplant (transplant using donor cells) that can affect many organs. This presentation describes how GVHD can affect the gut, and strategies to prevent and treat it.

Graft-versus-host-disease (GVHD) can be a significant problem after stem cell transplantation. This presentation discusses what GVHD is, risk factors for developing it and recent advances in the prevention and treatment of GVHD.

This presentation discusses CAR T-cell therapy for multiple myeloma. It explains what CAR T-cell therapy is, the process, and what clinical trials are indicating in regards to short- and long-term side effects, patient outcomes, and quality of life.

CAR T cell therapy has become an increasingly common treatment for patients with diffuse large B-cell lymphoma, (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma. This presentation discusses how it works, who is a good candidates for CAR T-cell therapy, and the risks and benefits of the treatment.